The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Respiratory Medicine

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rmed.2009.03.008PMID 19362459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis

  2009cited by this paper
• Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.

  2009cited by this paper
• Safety and tolerability of omalizumab

  2009cited by this paper
• The use of omalizumab in asthma.

  2008cited by this paper
• Pre-treatment Specific IgE levels are not Useful in Predicting a Response to Omalizumab Therapy

  2008cited by this paper
• Asthma 2008: Targeting Immunoglobulin E to Achieve Disease Control

  2008cited by this paper
• IgE in allergy and asthma today

  2008cited by this paper
• Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

  2008cited by this paper
• Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

  2008cited by this paper
• An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthma

  2008cited by this paper
• Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma

  2008cited by this paper
• American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.

  2007cited by this paper
• The unusual suspects: a surprise regarding reactions to omalizumab.

  2007cited by this paper
• Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

  2007cited by this paper
• Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

  2007cited by this paper
• Severe serum sickness-like syndrome after omalizumab therapy for asthma.

  2007cited by this paper
• Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

  2007cited by this paper
• How to evaluate a patient's response to anti-IgE

  2007cited by this paper
• CD‐sens and clinical changes during withdrawal of Xolair after 6 years of treatment

  2007cited by this paper
• Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.

  2007cited by this paper
• Predicting and evaluating response to omalizumab in patients with severe allergic asthma.

  2007cited by this paper
• Omalizumab Reduced Need for Steroid Bursts in Asthmatics Concomitantly Using Leukotrine Receptor Antagonists (LTRAs)

  2006cited by this paper
• Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists.

  2006cited by this paper
• Anti-IgE for chronic asthma in adults and children.

  2006cited by this paper
• Systemic reaction to omalizumab.

  2006cited by this paper
• Anti-IgE for chronic asthma in adults and children.

  2006cited by this paper
• Anaphylaxis, killer allergy: long-term management in the community.

  2006cited by this paper
• Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications.

  2006cited by this paper
• The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.

  2005cited by this paper
• Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

  2005cited by this paper
• The diagnosis and management of anaphylaxis: an updated practice parameter.

  2005cited by this paper
• PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA: RESULTS FROM A MULTINATIONAL STUDY

  2005cited by this paper
• Omalizumab is well tolerated in adolescent/adult patients (≥12 Years) with moderate-to-severe persistent asthma

  2005cited by this paper
• The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

  2005cited by this paper
• Effect of a concomitant diagnosis of allergic rhinitis on asthma‐related health care use by adults

  2005cited by this paper
• Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma

  2004cited by this paper
• Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

  2004cited by this paper
• Relationship between quality of life and clinical status in asthma: a factor analysis

  2004cited by this paper
• A Critical Role for Eosinophils in Allergic Airways Remodeling

  2004cited by this paper
• Asthma severity and medical resource utilisation

  2004cited by this paper
• Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.

  2004cited by this paper
• Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

  2004cited by this paper
• Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils

  2004cited by this paper
• Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

  2004cited by this paper
• Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma.

  2004cited by this paper
• Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

  2004cited by this paper
• Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

  2004cited by this paper
• Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils

  2004cited by this paper
• 4. IgE, mast cells, basophils, and eosinophils.

  2003cited by this paper
• Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

  2003cited by this paper
• IgE, mast cells, basophils, and eosinophils.

  2003cited by this paper
• Systematic assessment of difficult-to-treat asthma

  2003cited by this paper
• Allergic and nonallergic forms of atopic diseases.

  2003cited by this paper
• Links between rhinitis and asthma

  2003cited by this paper
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

  2003cited by this paper
• Omalizumab is effective in the long-term control of severe allergic asthma.

  2003cited by this paper
• Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

  2002cited by this paper
• Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma.

  2002cited by this paper
• Costs of asthma are correlated with severity: a 1-yr prospective study

  2002cited by this paper
• Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

  2001cited by this paper
• The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

  2001cited by this paper
• Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

  2001cited by this paper
• Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society.

  2000cited by this paper
• Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.

  2000cited by this paper
• Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma

  1999cited by this paper
• B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation.

  1999cited by this paper
• Features that distinguish those who die from asthma from community controls with asthma.

  1998cited by this paper
• Costs of asthma according to the degree of severity.

  1998cited by this paper
• Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

  1997cited by this paper
• Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.

  1997cited by this paper
• Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.

  1997cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

  1995cited by this paper
• Inhibition of allergic reactions with antibodies to IgE.

  1995cited by this paper
• Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

  1994cited by this paper
• The binding site on human immunoglobulin E for its high affinity receptor.

  1994cited by this paper
• Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

  1992cited by this paper
• Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis

  1991cited by this paper

• Defense mechanisms in immune-mediated diseases: a cross-sectional study focusing on Severe Allergic Asthma and Hymenoptera Venom Anaphylaxis patients

  2025cites this paper
• The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3 + Tregs

  2025cites this paper
• Generation of a virus‐like particles based vaccine against IgE

  2024cites this paper
• Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

  2024cites this paper
• IgE-FcεRI protein-protein interaction as a therapeutic target against allergic asthma: An updated review.

  2024cites this paper
• B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment

  2023cites this paper
• Regulation of Trafficking and Signaling of the High Affinity IgE Receptor by FcεRIβ and the Potential Impact of FcεRIβ Splicing in Allergic Inflammation

  2022cites this paper
• Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation

  2022cites this paper
• Omalizumab and IgE in the Control of Severe Allergic Asthma

  2022cites this paper
• Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

  2022cites this paper
• Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response

  2022cites this paper
• Anti-IgE: A treatment option in allergic rhinitis?

  2021cites this paper
• Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex

  2021cites this paper
• Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study

  2021cites this paper
• Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.

  2021cites this paper
• Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome

  2020cites this paper
• Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level

  2020cites this paper
• A robust and stable reporter gene bioassay for anti-IgE antibodies

  2020cites this paper
• High dose omalizumab use in patients with chronic spontaneous urticaria.

  2020cites this paper
• The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils

  2020cites this paper
• Switching between biologics in severe asthma patients. When the first choice is not proven to be the best

  2020cites this paper
• Past, present, and future of anti‐IgE biologics

  2020cites this paper
• Biologics for Asthma and Risk of Infection: Cause for Concern?

  2019cites this paper
• Long-Term Evaluation of Response to Omalizumab Therapy in Real-Life by a Novel Multi-Modular Approach - The REALITY Study.

  2019cites this paper
• Phenotypes and endotypes of adult asthma: Moving toward precision medicine.

  2019cites this paper
• Combination Biologic Therapy for Severe Persistent Asthma.

  2019cites this paper
• IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.

  2019cites this paper
• Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

  2019cites this paper
• Anti-allergic Drugs

  2019cites this paper
• Immunomodulators and Biologics: Beyond Stepped-Care Therapy.

  2019cites this paper
• New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?

  2019cites this paper
• Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma

  2019cites this paper
• Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.

  2018cites this paper
• Targeting IgE in allergic disease.

  2018cites this paper
• Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits.

  2018cites this paper
• Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.

  2018cites this paper
• Successful long-term, adjunctive use of guaifenesin in a patient with a complex atopic medical history and primary immune deficiency: A case report

  2018cites this paper
• The effect of mindfulness-based cognitive therapy on mindfulness and quality of life for patients with asthma

  2018cites this paper
• Fungal Rhinosinusitis

  2018cites this paper
• Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma

  2018cites this paper
• Biologics in allergic and immunologic diseases: Promises and challenges in the era of personalized medicine.

  2018cites this paper
• Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

  2017cites this paper
• IgE and eosinophils as therapeutic targets in asthma

  2017cites this paper
• "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.

  2017cites this paper
• Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

  2017cites this paper
• Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study

  2016cites this paper
• ‘Real‐life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

  2016cites this paper
• Treating IgE‐mediated diseases via targeting IgE‐expressing B cells using an anti‐CεmX antibody

  2016cites this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

  2016cites this paper
• Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?

  2016cites this paper
• From IgE to Omalizumab

  2016cites this paper
• Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.

  2016cites this paper
• Omalizumab in the Treatment of Bullous Pemphigoid - State of the Art

  2016cites this paper
• Biomarkers in the clinical development of asthma therapies.

  2016cites this paper
• Current and Future Asthma Treatments: Phenotypical Approach on the Path to Personalized Medicine in Asthma

  2016cites this paper
• An Overview of Pediatric Asthma

  2016cites this paper
• Omalizumab and treatment-resistant chronic spontaneous urticaria

  2015cites this paper
• Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma.

  2015cites this paper
• Personalized health care beyond oncology: new indications for immunoassay‐based companion diagnostics

  2015cites this paper
• The Link between Uncontrolled Asthma and Sensitization to Inhalant Allergens: Evidence from Jeddah, Saudi Arabia

  2015cites this paper
• Optimisation of Omalizumab Dosage in Patients with Severe Persistent Allergic Asthma Using recoveryELISA

  2014cites this paper
• Connections of Reduced Performance Health Data for Severe Persistent Uncontrolled Allergic Asthma Treated by Omazulimab

  2014influential citation
• Disease-Modifikation und Dauer einer Omalizumab-Therapie bei Patienten mit schwerem allergischen Asthma

  2014cites this paper
• Newer strategies in the management of asthma.

  2014cites this paper
• СОВРЕМЕННЫЕ ПРОЯВЛЕНИЯ ЭПИДЕМИЧЕСКОГО ПРОЦЕССА И ОСОБЕННОСТИ ТЕЧЕНИЯ АТОПИЧЕСКОГО ДЕРМАТИТА

  2014cites this paper
• Newer strategies in the management of asthma.

  2014cites this paper
• НЕКОТОРЫЕ КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКИЕ АСПЕКТЫ ТЕЧЕНИЯ АТОПИЧЕСКОГО ДЕРМАТИТА НА ТЕРРИТОРИИ ПЕНЗЕНСКОЙ ОБЛАСТИ

  2014cites this paper
• A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.

  2014cites this paper
• Evaluation of needle acupuncture actions on clinical improvement, pulmonary functions, and cytokines of asthmatic children

  2013cites this paper
• The influence of commensal bacteria-derived signals on basophil-associated allergic inflammation

  2013cites this paper
• Treatments in Infectious and Allergic Conjunctivitis: Is Immunomodulation the Future?

  2013cites this paper
• Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.

  2013cites this paper
• Sputum IgE and Cytokines in Asthma: Relationship with Sputum Cellular Profile

  2013cites this paper
• Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies.

  2013cites this paper
• THE RECOVERY-ELISA—A NOVEL ASSAY TECHNIQUE TO MONITOR THERAPY WITH HUMANIZED ANTIBODIES: THE EXAMPLE OF OMALIZUMAB

  2013cites this paper
• Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry

  2013cites this paper
• Severe asthma: an expanding and mounting clinical challenge.

  2013cites this paper
• Inhaled proteins: challenges and perspectives.

  2013cites this paper
• Monoclonal antibodies for asthma and chronic obstructive pulmonary disease

  2013cites this paper
• Asthmatherapie mit Biologika – Stand der Entwicklung

  2013cites this paper
• Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells

  2013cites this paper
• Redefining approaches to asthma: developing targeted biologic therapies.

  2013cites this paper
• Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational Trial.

  2013influential citation
• Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents.

  2013cites this paper
• Itraconazole as ‘bridge therapy’ to anti-IgE in a patient with severe asthma with fungal sensitisation

  2013cites this paper
• Airway Hyperresponsiveness: New Insights into the Pathogenesis

  2012cites this paper
• Commensal bacterial–derived signals regulate basophil hematopoiesis and allergic inflammation

  2012cites this paper
• Mechanisms Mediating Asthma Tolerance Induced By Regulatory Dendritic Cells Through CD4+CD25+Foxp3+ T Regulatory Cells

  2012cites this paper
• Omalizumab no tratamento da asma brônquica alérgica: Experiência num Serviço de Imunoalergologia

  2012cites this paper
• Omalizumab: Clinical Use for the Management of Asthma

  2012cites this paper
• Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.

  2012cites this paper
• Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.

  2012cites this paper
• Addressing patient-specific treatment needs in asthma management

  2012cites this paper
• Effectiveness of Omalizumab in a Patient with Severe Asthma, Low Serum IgE Level, and Lack of Sensitized Allergens Induced by Oral Steroid Therapy: The Usefulness of Impulse Oscillation for Assessment of Omalizumab Therapy

  2012cites this paper
• Omalizumab as monotherapy for refractory chronic idiopathic urticaria: A prospective noncomparative open study from Kuwait

  2012cites this paper
• Patologías mediadas por la inmunoglobulina E: de la inmunoglobulina E al omalizumab

  2012cites this paper
• Novel Drugs for Asthma Treatment: Immunomodulatory Therapy

  2012cites this paper
• Anti igE thErApy in AllErgic AsthmA And AllErgic rhinitis

  2012cites this paper
• Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches

  2012cites this paper
• Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

  2012cites this paper